Biochimica et Biophysica Acta-Reviews on Cancer

Papers
(The H4-Index of Biochimica et Biophysica Acta-Reviews on Cancer is 44. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
Fibrosis and cancer: A strained relationship306
Diagnostic, prognostic, and therapeutic significance of long non-coding RNA MALAT1 in cancer170
Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting166
Cholesterol metabolism: New functions and therapeutic approaches in cancer159
Advances in clinical immunotherapy for gastric cancer138
Roles of CA19-9 in pancreatic cancer: Biomarker, predictor and promoter127
Roles of CA125 in diagnosis, prediction, and oncogenesis of ovarian cancer117
Altered glycosylation in cancer: A promising target for biomarkers and therapeutics114
Elucidating the mechanisms of Temozolomide resistance in gliomas and the strategies to overcome the resistance.103
Non-coding RNAs and potential therapeutic targeting in cancer102
Targeting tumor microenvironment in ovarian cancer: Premise and promise100
The implication of long non-coding RNAs in the diagnosis, pathogenesis and drug resistance of pancreatic ductal adenocarcinoma and their possible therapeutic potential99
Progress and challenges of immunotherapy in triple-negative breast cancer94
Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: From bench to bedside93
Lenvatinib for hepatocellular carcinoma: From preclinical mechanisms to anti-cancer therapy91
Effect of probiotics and gut microbiota on anti-cancer drugs: Mechanistic perspectives91
Caspase-8: The double-edged sword86
Cholesterol and beyond - The role of the mevalonate pathway in cancer biology80
The emerging role of paraptosis in tumor cell biology: Perspectives for cancer prevention and therapy with natural compounds75
Understanding and advancement in gold nanoparticle targeted photothermal therapy of cancer72
Targeting pyruvate dehydrogenase kinase signaling in the development of effective cancer therapy70
HER2-targeted therapies in gastric cancer70
Therapeutic resistance of pancreatic cancer: Roadmap to its reversal65
Targeting tumor-associated macrophages for cancer immunotherapy64
The role of N6-methyladenosine mRNA in the tumor microenvironment63
Priming the tumor immune microenvironment with chemo(radio)therapy: A systematic review across tumor types62
Oncometabolites lactate and succinate drive pro-angiogenic macrophage response in tumors55
Gambogic acid: A shining natural compound to nanomedicine for cancer therapeutics54
Genomic instability, inflammatory signaling and response to cancer immunotherapy54
New insights on sorafenib resistance in liver cancer with correlation of individualized therapy53
Metabolic reprogramming in renal cancer: Events of a metabolic disease53
Tumor-associated neutrophils and neutrophil-targeted cancer therapies53
The RNA m6A writer METTL14 in cancers: Roles, structures, and applications52
The clinical relevance of gene expression based prognostic signatures in colorectal cancer51
Pharmacological significance of the non-canonical NF-κB pathway in tumorigenesis51
PTEN in osteosarcoma: Recent advances and the therapeutic potential50
Immunotherapy for advanced hepatocellular carcinoma, where are we?50
Challenge and countermeasures for EGFR targeted therapy in non-small cell lung cancer50
Long non-coding RNAs and cancer metastasis: Molecular basis and therapeutic implications48
Communication in tiny packages: Exosomes as means of tumor-stroma communication48
HOX genes function in Breast Cancer development46
Advances in cancer cachexia: Intersection between affected organs, mediators, and pharmacological interventions46
Combinatorial therapy in tumor microenvironment: Where do we stand?45
The emerging role of miRNA clusters in breast cancer progression45
Non-mitotic functions of polo-like kinases in cancer cells44
LOXL2 in cancer: regulation, downstream effectors and novel roles44
0.12687993049622